Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program

被引：21

作者：

Mazurek, Michal ^{[1
]}

Teutsch, Christine ^{[2
]}

Diener, Hans-Christoph ^{[3
]}

Dubner, Sergio J. ^{[4
]}

Halperin, Jonathan L. ^{[5
]}

Ma, Chang-Sheng ^{[6
]}

Rothman, Kenneth J. ^{[7
]}

Paquette, Miney ^{[8
]}

Zint, Kristina ^{[9
]}

Franca, Lionel Riou ^{[10
]}

Lu, Shihai ^{[11
]}

Bartels, Dorothee B. ^{[12
]}

Huisman, Menno V. ^{[13
]}

Lip, Gregory Y. H. ^{[14
,15
]}

机构：

[1] Silesian Med Univ, Congenital Heart Dis & Electrotherapy, Dept Cardiol, Silesian Ctr Heart Dis, Zabrze, Poland

[2] Boehringer Ingelheim Int GmbH, Therapeut Area Cardiometab, Dept Clin Dev & Med Affairs, Ingelheim, Germany

[3] Univ Duisburg Essen, Dept Neurol, Essen, Germany

[4] Clin & Maternidad Suizo Argentina, Buenos Aires, DF, Argentina

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] Capital Med Univ, Beijing AnZhen Hosp, Atrial Fibrillat Ctr, Cardiol Dept, Beijing, Peoples R China

[7] RTI Hlth Solut, Res Triangle Pk, NC USA

[8] Boehringer Ingelheim GmbH & Co KG, Dept Med, Burlington, ON, Canada

[9] Boehringer Ingelheim Int GmbH, Global Epidemiol Dept, Ingelheim, Germany

[10] Sanofi Aventis, Chilly Mazarin, France

[11] Boehringer Ingelheim Pharmaceut Inc, Biostat & Data Sci Dept, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[12] Hannover Med Sch, Hannover, Germany

[13] Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Leiden, Netherlands

[14] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England

[15] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England

来源：

AMERICAN HEART JOURNAL | 2019年 / 218卷

关键词：

ATRIAL-FIBRILLATION; MORTALITY RISKS; WARFARIN; STROKE; EVENTS;

D O I：

10.1016/j.ahj.2019.08.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases, assessing long-term safety and effectiveness of dabigatran etexilate (dabigatran) in patients with newly diagnosed atrial fibrillation (AF) in clinical practice. This report provides the final analysis of 2-year clinical outcomes of the full cohort of 4873 patients prescribed dabigatran and followed for a mean of 18.0 +/- 9.4 months out of the 15,308 eligible patients enrolled in Phase II (2011-2014). The overall incidence rates per 100 person-years were: stroke 0.65 (95% CI 0.48-0.87), major bleeding 0.97 (0.76-1.23) and myocardial infarction (MI) 0.50 (0.35.0.69), with observed event rates broadly consistent in all study regions, which confirms the sustained safety and effectiveness of dabigatran over 2 years of observation in clinical practice.

引用

页码：123 / 127

页数：5

共 50 条

[21] Characteristics of Patients With Asymptomatic Atrial Fibrillation and Ischemic Stroke-Insights From the GLORIA-AF Registry (Phase 2)
Heer, Tobias
Zeymer, Uwe
Schwarzbach, Christopher J.
Seidl, Karlheinz
Rauch-Kroehnert, Ursula
Marler, Sabrina
Teutsch, Christine
Diener, Hans-Christoph
Senges, Jochen
Lip, Gregory Y. H.
Huisman, Menno V.
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2025, 48 (01): : 42 - 49
[22] Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry
Bergler-Klein, Jutta
Gotcheva, Nina
Kalejs, Oskars
Kalarus, Zbigniew
Kovacic, Dragan
Persic, Viktor
Shlyakhto, Evgeny
Uuetoa, Tiina
Huisman, Menno V.
Lip, Gregory Y. H.
Vinereanu, Dragos
AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (01) : e1 - e12
[23] Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIA-AF registry
Dubner, S. J.
Huisman, M. V.
Diener, H. C.
Halperin, J. L.
Rothman, K. J.
Ma, C. S.
Bergler-Klein, J.
Zint, K.
Franca, L. Riou
Lu, S.
Teutsch, C.
Paquette, M.
Lip, G. Y. H.
EUROPEAN HEART JOURNAL, 2018, 39 : 606 - 607
[24] Impact of chronic obstructive pulmonary disease on the natural history of atrial fibrillation: a report from the GLORIA-AF registry phase II & III
Romiti, G. F.
Proietti, M.
Corica, B.
Mei, D. A.
Frost, F.
Bisson, A.
Boriani, G.
Olshansky, B.
Chao, T. F.
Huisman, M. V.
Lip, G. Y. H.
EUROPEAN HEART JOURNAL, 2023, 44
[25] Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
Gregory Y. H. Lip
Agnieszka Kotalczyk
Christine Teutsch
Hans-Christoph Diener
Sergio J. Dubner
Jonathan L. Halperin
Chang-Sheng Ma
Kenneth J. Rothman
Sabrina Marler
Venkatesh Kumar Gurusamy
Menno V. Huisman
Clinical Research in Cardiology, 2022, 111 : 593 - 593
[26] Patterns of pharmacological treatment in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF Registry Phase III
Corica, Bernadette
Romiti, Giulio Francesco
Boriani, Giuseppe
Olshansky, Brian
Chao, Tze-Fan
Huisman, Menno V.
Proietti, Marco
Lip, Gregory Y. H.
GLORIA AF Investigators
BMC MEDICINE, 2025, 23 (01):
[27] Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: results from phase II/III of the GLORIA-AF registry
Ding, W. Y.
Lane, D. A.
Gupta, D.
Huisman, M. V.
Lip, G. Y. H.
EUROPEAN HEART JOURNAL, 2022, 43 : 516 - 516
[28] Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry
Corica, Bernadette
Romiti, Giulio Francesco
Proietti, Marco
Mei, Davide Antonio
Boriani, Giuseppe
Chao, Tze-Fan
Olshansky, Brian
V. Huisman, Menno
Lip, Gregory Y. H.
MAYO CLINIC PROCEEDINGS, 2024, 99 (06) : 927 - 939
[29] Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry
Ding, Wern Yew
Lane, Deirdre A.
Gupta, Dhiraj
Huisman, Menno V.
Lip, Gregory Y. H.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (15):
[30] Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA-AF registry phase III
Liu, Yang
Chen, Yang
Lam, Steven H. M.
Huang, Bi
Romiti, Giulio F.
Alam, Uazman
Chao, Tze Fan
Olshansky, Brian
Hong, Kui
Huisman, Menno V.
Lip, Gregory Y. H.
DIABETES OBESITY & METABOLISM, 2024, 26 (12): : 5795 - 5804

← 1 2 3 4 5 →